Healthcare Industry News:  Merit Medical Systems 

Devices Interventional Acquisitions

 News Release - April 13, 2006

Merit Medical Acquires New Hemostasis Valve

SOUTH JORDAN, Utah--(HSMN NewsFeed)--April 13, 2006--Merit Medical Systems Inc. (Nasdaq: MMSI ), a leading manufacturer and marketer of proprietary disposable accessories used primarily in cardiology and radiology procedures, announced today that it has completed for cash an asset acquisition of a hemostasis valve from Millimed A/S, a Danish corporation.

Hemostasis valves are used during interventional procedures to allow passage into the vasculature of various devices, including stents and PTCA balloons, while minimizing the loss of blood. The new product extends Merit's leadership position in this product area and is complementary to Merit's inflation device business. Regulatory approvals are in place with market release estimated to be in early May.

"This product, which will be marketed under the Honor(TM) brand name, will be the first of its type in the United States although it has been marketed in Europe for several years," said Fred P. Lampropoulos, Merit's chairman and CEO. "Our initial impressions from U.S. physicians have been positive."

Production of the product will be located in Merit's facility in Galway, Ireland. The agreement calls for transfer and startup requirements with a maximum payment of $1.5 million.

About Merit

Founded in 1987, Merit Medical Systems Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical accessories used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 85 individuals. Merit employs approximately 1,600 people worldwide, with facilities in Salt Lake City and South Jordan, Utah; Angleton, Texas; Richmond, Va.; Maastricht, Netherlands; Venlo, Netherlands; and Galway, Ireland.

Statements contained in this release which are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended Dec. 31, 2005. Such risks and uncertainties include market acceptance of new products, introduction of products in a timely fashion, product recalls, delays in obtaining regulatory approvals, or the failure to maintain such approvals, cost increases, fluctuations in and obsolescence of inventory, price and product competition, availability of labor and materials, development of new products and technology that could render our products obsolete, product liability claims, modification or limitation of governmental or private insurance reimbursement, infringement of our technology or the assertion that our technology infringes the rights of other parties, foreign currency fluctuations, challenges associated with the company's growth strategy, changes in health care markets related to health care reform initiatives, litigation and other factors referred to in the company's 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to the company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.

Source: Merit Medical Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.